Tratamento com Toxina Botulínica em pacientes pós acidente vascular cerebral no CREFES
DOI:
https://doi.org/10.11606/issn.2317-0190.v31iSupl.1a225181Palavras-chave:
Toxinas Botulínicas Tipo A, Acidente Vascular Cerebral, Espasticidade Muscular, DistoniaResumo
Espasticidade é uma complicação comum após um Acidente Vascular Cerebral (AVC), afetando cerca de 25% dos sobreviventes. Compromete a qualidade de vida, causando rigidez muscular, postura inadequada dos membros, dor, dificuldade de higiene e limitações no auto-cuidado e tarefas diárias. O uso da toxina botulínica tipo A (TBA) é tratamento padrão para esta condição embora ainda pouco difundido. É um tratamento eficaz, seguro, trazendo inúmeros benefícios, como o ganho de função e a melhora na qualidade de vida.
Downloads
Referências
Levy J, Karam P, Forestier A, Loze JY, Bensmail D. Botulinum toxin use in patients with post-stroke spasticity: a nationwide retrospective study from France. Front Neurol. 2023;14:1245228. Doi: https://doi.org/10.3389/fneur.2023.1245228
Francisco GE, Balbert A, Bavikatte G, Bensmail D, Carda S, Deltombe T, et al. A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus. J Rehabil Med. 2021;53(1):jrm00134. Doi: https://doi.org/10.2340/16501977-2753
Bavikatte G, Subramanian G, Ashford S, Allison R, Hicklin D. Early Identification, Intervention and Management of Post-stroke Spasticity: Expert Consensus Recommendations. J Cent Nerv Syst Dis. 2021;13:11795735211036576. Doi: https://doi.org/10.1177/11795735211036576
Wissel J, Kivi A. Post-Stroke Spastic Movement Disorder and Botulinum Toxin A Therapy: Early Detection And Early Injection. Ann Rehabil Med. 2023;47(5):326-336. Doi: https://doi.org/10.5535/arm.23108
Khan P, Riberto M, Frances JA, Chueire R, Amorim ACFG, Xerez D, et al. The Effectiveness of Botulinum Toxin Type A (BoNT-A) Treatment in Brazilian Patients with Chronic Post-Stroke Spasticity: Results from the Observational, Multicenter, Prospective BCause Study. Toxins (Basel). 2020;12(12):770. Doi: https://doi.org/10.3390/toxins12120770
Trompetto C, Marinelli L, Mori L, Bragazzi N, Maggi G, Cotellessa F, et al. Increasing the Passive Range of Joint Motion in Stroke Patients Using Botulinum Toxin: The Role of Pain Relief. Toxins (Basel). 2023;15(5):335. Doi: https://doi.org/10.3390/to-xins15050335
Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, et al. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. J Rehabil Med. 2021;53(2):jrm00157. Doi: https://doi.org/10.2340/16501977-2801
Picelli A, Santamato A, Chemello E, Cinone N, Cisari C, Gandolfi M, et al. Adjuvant treatments associated with botulinum toxin injection for managing spasticity: An overview of the literature. Ann Phys Rehabil Med. 2019;62(4):291-296. Doi: https://doi.org/10.1016/j.rehab.2018.08.004
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2024 Acta Fisiátrica
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
